Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Relypsa Adds Venture Funds In Another Effort To Reach Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.

You may also be interested in...

Biotech IPO Candidates Ramp Up To Get Out Before The Holidays

After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.

Financings Of The Fortnight Looks Ahead To The Annual Survey Of Life Sciences Venture Capital Firms

Plus news on recent financing activity by Novira Therapeutics, MediciNova, Elcelyx Therapeutics and Relypsa.

Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads

It was a good day for biotech venture news, as early-stage investor Third Rock closed its second fund and Relypsa reported a massive $70 million Series B funding to push its potassium binding agent into pivotal trials.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts